Rona Therapeutics Receives IND Clearance from FDA to Initiate Phase 2 Study of RN0361: an APOC3 Targeted siRNA for Management of Hypertriglyceridemia

Rona Therapeutics China New York

View original content:https://www.prnewswire.co.uk/news-releases/rona-therapeutics-receives-ind-clearance-from-fda-to-initiate-phase-2-study-of-rn0361-an-apoc3-targeted-sirna-for-management-of-hypertriglyceridemia-302402731.html